Quest Diagnostics (DGX) Stratify JCV gets de novo classification from FDA

- 0 0

1538 12 tahun lalu

karmastock | 0 Pelanggan

1538 12 tahun lalu

Quest Diagnostics Inc - DGX - reported that the FDA has granted a de novo classification petition to its STRATIFY JCV Antibody ELISA testing service.

Tags: NYSE:DGX DGX Biogen leukoencephalopathy polyomavirus STRATIFY-JCV

KOMENTAR

0